Immunologic approaches to cancer prevention - Current status, challenges, and future perspectives

Seminars in Oncology

Volumn 43, Issue 1, 2016, Pages 161-172

  Wojtowicz, Malgorzata E ^a   Dunn, Barbara K ^a   Umar, Asad ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer immunoprevention; Cancer vaccines; Tumor antigens; Tumor immunity

Indexed keywords

ALPHA LACTALBUMIN; CANCER VACCINE; CARBOXY TERMINAL PEPTIDE; DENDRITIC CELL VACCINE; DNA VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; HLA A2 ANTIGEN; HLA A3 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MAMMAGLOBIN A; MUCIN 1; MUCIN 1 PEPTIDE; MULTIVALENT VACCINE; NELIPEPIMUT S; PEPTIDE VACCINE; SOMATOMEDIN C RECEPTOR; TELOMERASE REVERSE TRANSCRIPTASE; TUMOR ANTIGEN; UNCLASSIFIED DRUG; AUTOANTIGEN; ERBB2 PROTEIN, HUMAN; HEPATITIS B VACCINE; LACTALBUMIN; TELOMERASE; TERT PROTEIN, HUMAN; WART VIRUS VACCINE;

ADAPTIVE IMMUNITY; BREAST CANCER; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PREVENTION; CARCINOGENESIS; COLON CANCER; COLORECTAL CANCER; DISEASE FREE SURVIVAL; DRUG EFFECT; DRUG TARGETING; FRAMESHIFT MUTATION; GENETIC RISK; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOEDITING; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOSURVEILLANCE; INFECTION; INNATE IMMUNITY; INTRADUCTAL CARCINOMA; METASTASIS; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; WART VIRUS; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; FEMALE; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; PANCREAS TUMOR;

ADAPTIVE IMMUNITY; ANIMALS; ANTIGENS, NEOPLASM; AUTOANTIGENS; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; FEMALE; FRAMESHIFT MUTATION; HEPATITIS B VACCINES; HUMANS; IMMUNITY, INNATE; IMMUNOLOGIC SURVEILLANCE; IMMUNOTHERAPY; LACTALBUMIN; MAMMAGLOBIN A; PANCREATIC NEOPLASMS; PAPILLOMAVIRUS VACCINES; RECEPTOR, ERBB-2; TELOMERASE;

EID: 84960464701     PISSN: 00937754     EISSN: 15328708     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2015.11.001     Document Type: Review

References (127)

1. W.B. Coley The treatment of malignant tumors by repeated inoculations of erysipelas: with a report of ten original cases Am J Med Sci. 105 1893 487 511
2. Nathanson Spontaneous regression of malignant melanoma: a review of the literature on incidence, clinical features, and possible mechanisms Natl Cancer Inst Monogr 44 1976 67 76
3. J.M. Kirkwood, L.H. Butterfield, A.A. Tarhini, H. Zarour, P. Kalinski, and S. Ferrone Immunotherapy of cancer in 2012 CA Cancer J Clin 62 5 2012 309 335
4. D. Pardoll Cancer and the immune system: basic concepts and targets for intervention Semin Oncol. 42 4 2015 523 538
5. O.J. Finn Immuno-oncology: understanding the function and dysfunction of the immune system in cancer Ann Oncol 23 Suppl 8 2012 viii6-9
6. J.R. Brahmer, S.S. Tykodi, L.Q. Chow, and et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N Engl J Med. 366 26 2012 2455 2465
7. S.L. Topalian, F.S. Hodi, J.R. Brahmer, and et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med. 366 26 2012 2443 2454
8. M.B. Atkins, and M. Sznol Cancer immunotherapy: past progress and future directions Semin Oncol. 42 4 2015 518 522
9. C.G. Drake Combined immune checkpoint blockade Semin Oncol. 42 4 2015 656 662
10. M.K. Callahan, and J.D. Wolchok Clinical activity, toxicity, biomarkers, and future development of CTLA-4 checkpoint antagonists Semin Oncol. 42 4 2015 573 586
11. J. Obeid, Y. Hu, and C.L. Slingluff Jr Vaccines, adjuvants, and dendritic cell activators-current status and future challenges Semin Oncol. 42 4 2015 549 561
12. O.E. Rahma, E. Gammoh, R.M. Simon, and S.N. Khleif Is the "3+3" dose-escalation phase I clinical trial design suitable for therapeutic cancer vaccine development? A recommendation for alternative design Clin Cancer Res. 20 18 2014 4758 4767
13. E. Vivier, D.H. Raulet, A. Moretta, and et al. Innate or adaptive immunity? The example of natural killer cells Science 331 6013 2011 44 49
14. K. Hoebe, E. Janssen, and B. Beutler The interface between innate and adaptive immunity Nat Immunol. 5 10 2004 971 974
15. KP Murphy Janeway's immunobiology. 8th ed New York, NY: Garland Science, Taylor & Francis Group 2012
16. M.A. Murphy, J.J. O'Leary, and D.J. Cahill Assessment of the humoral immune response to cancer J Proteomics 75 15 2012 4573 4579
17. M.L. Disis Immune regulation of cancer J Clin Oncol. 28 29 2010 4531 4538
18. T. Kawai, and S. Akira The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors Nat Immunol. 11 5 2010 373 384
19. K. Clark Protein kinase networks that limit TLR signalling Biochem Soc Trans. 42 1 2014 11 24
20. H. Lu TLR agonists for cancer immunotherapy: tipping the balance between the immune stimulatory and inhibitory effects Front Immunol 5 2014 83
21. H. Shirota, and D.M. Klinman TLR-9 agonist immunostimulatory sequence adjuvants linked to cancer antigens Methods Mol Biol. 1139 2014 337 344
22. H.L. Ploegh Logic of the immune system Cancer Immunol Res 1 1 2013 OF4 OF9
23. CA Janeway Jr, P Travers, M Walport, and MJ Shlomchik Immunobiology. Ed. 5. The immune system in health and disease New York, NY: Garland Science 2001
24. F.S. Hodi, S.J. O'Day, D.F. McDermott, and et al. Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med. 363 8 2010 711 723
25. S.A. Funt, D.B. Page, J.D. Wolchok, and M.A. Postow CTLA-4 antibodies: new directions, new combinations Oncology (Williston Park) 28 Suppl 3 2014 6 14
26. K.A. Reiss, P.M. Forde, and J.R. Brahmer Harnessing the power of the immune system via blockade of PD-1 and PD-L1: a promising new anticancer strategy Immunotherapy 6 4 2014 459 475
27. C.S. Lee, M. Cragg, M. Glennie, and P. Johnson Novel antibodies targeting immune regulatory checkpoints for cancer therapy Br J Clin Pharmacol. 76 2 2013 233 247
28. M. Burnet Cancer; a biological approach. I. The processes of control Br Med J. 1 5022 1957 779 786
29. G.P. Dunn, A.T. Bruce, H. Ikeda, L.J. Old, and R.D. Schreiber Cancer immunoediting: from immunosurveillance to tumor escape Nat Immunol. 3 11 2002 991 998
30. R.D. Schreiber, L.J. Old, and M.J. Smyth Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion Science 331 6024 2011 1565 1570
31. D. Mittal, M.M. Gubin, R.D. Schreiber, and M.J. Smyth New insights into cancer immunoediting and its three component phases - elimination, equilibrium and escape Curr Opin Immunol. 27 2014 16 25
32. IARC. Available from: http://www.iarc.fr/en/publications/pdfs-online/epi/cancerepi/CancerEpi-16.pdf.
33. M.H. Chang, C.J. Chen, M.S. Lai, and et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group N Engl J Med. 336 26 1997 1855 1859
34. J. Dillner, S.K. Kjaer, C.M. Wheeler, and et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial BMJ 341 2010 c3493
35. M. Lehtinen, J. Paavonen, C.M. Wheeler, and et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial Lancet Oncol. 13 1 2012 89 99
36. A.R. Giuliano, J.M. Palefsky, S. Goldstone, and et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males N Engl J Med. 364 5 2011 401 411
37. J.M. Palefsky, A.R. Giuliano, S. Goldstone, and et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia N Engl J Med. 365 17 2011 1576 1585
38. FDA. F.D.A. approval of nonavalent HPV vaccine adds new tool to eradicate cervical cancer 2014 [cited 2015 September 11]. Available from: https://www.sgo.org/newsroom/news-releases/fda-approval-of-nonavalent-hpv-vaccine-adds-new-tool-to-eradicate-cervical-cancer/.
39. A.K. Chaturvedi, E.A. Engels, R.M. Pfeiffer, and et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States J Clin Oncol. 29 32 2011 4294 4301
40. A.P. Feinberg, and B. Vogelstein Hypomethylation of ras oncogenes in primary human cancers http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list-uids=6187346 Biochem Biophys Res Commun. 111 1 1983 47 54
41. K.V. Kowdley, S.C. Gordon, K.R. Reddy, and et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis N Engl J Med. 370 20 2014 1879 1888
42. J. Liu, A. Kosinska, M. Lu, and M. Roggendorf New therapeutic vaccination strategies for the treatment of chronic hepatitis B Virol Sin 29 1 2014 10 16
43. P.P. Ip, H.W. Nijman, J. Wilschut, and T. Daemen Therapeutic vaccination against chronic hepatitis C virus infection Antiviral Res. 96 1 2012 36 50
44. L.M.J. Law, A. Landi, W.C. Magee, D.L. Tyrrrell, and M. Houghton Progress towards a hepatitis C virus vaccine Emerging Microbes Infect 2 2013 e79
45. J.I. Cohen Epstein-Barr virus vaccines Clin Transl Immunol 4 1 2015 e32
46. G.G. Kenter, M.J. Welters, A.R. Valentijn, and et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia N Engl J Med. 361 19 2009 1838 1847
47. T.J. Kim, H.T. Jin, S.Y. Hur, and et al. Clearance of persistent HPV infection and cervical lesion by therapeutic DNA vaccine in CIN3 patients Nat Commun 5 2014 5317
48. P. Vici, L. Mariani, L. Pizzuti, and et al. Immunologic treatments for precancerous lesions and uterine cervical cancer J Exp Clin Cancer Res. 33 2014 29
49. Trimble CL, Morrow MP, Kraynyak KA, et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet. 2015;386(10008):2078-88
50. A. Venuti, G. Curzio, L. Mariani, and F. Paolini Immunotherapy of HPV-associated cancer: DNA/plant-derived vaccines and new orthotopic mouse models Cancer Immunol Immunother. 64 10 2015 1329 1338
51. J.W. Wang, C.F. Hung, W.K. Huh, C.L. Trimble, and R.B. Roden Immunoprevention of human papillomavirus-associated malignancies Cancer Prev Res (Phila) 8 2 2015 95 104
52. I. Martincorena, and P.J. Campbell Somatic mutation in cancer and normal cells Science 349 6255 2015 1483 1489
53. P.L. Lollini, G. Nicoletti, L. Landuzzi, and et al. Vaccines and other immunological approaches for cancer immunoprevention Curr Drug Targets. 12 13 2011 1957 1973
54. J.P. Marquez, S.E. Stanton, and M.L. Disis The antigenic repertoire of premalignant and high-risk lesions Cancer Prev Res (Phila) 8 4 2015 266 270
55. L. Delamarre, I. Mellman, and M. Yadav Cancer immunotherapy. Neo approaches to cancer vaccines Science 348 6236 2015 760 761
56. V.K. Tuohy Retired self-proteins as vaccine targets for primary immunoprevention of adult-onset cancers Expert Rev Vaccines. 13 12 2014 1447 1462
57. S.E. Stanton, and M.L. Disis Designing vaccines to prevent breast cancer recurrence or invasive disease Immunotherapy 7 2 2015 69 72
58. M.R. Hussein, and H.I. Hassan Analysis of the mononuclear inflammatory cell infiltrate in the normal breast, benign proliferative breast disease, in situ and infiltrating ductal breast carcinomas: preliminary observations J Clin Pathol. 59 9 2006 972 977
59. S.M. Mahmoud, E.C. Paish, D.G. Powe, and et al. Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer J Clin Oncol. 29 15 2011 1949 1955
60. S. Ladoire, L. Arnould, L. Apetoh, and et al. Pathologic complete response to neoadjuvant chemotherapy of breast carcinoma is associated with the disappearance of tumor-infiltrating foxp3+ regulatory T cells Clin Cancer Res. 14 8 2008 2413 2420
61. S. Liu, W.D. Foulkes, S. Leung, and et al. Prognostic significance of FOXP3+ tumor-infiltrating lymphocytes in breast cancer depends on estrogen receptor and human epidermal growth factor receptor-2 expression status and concurrent cytotoxic T-cell infiltration Breast Cancer Res. 16 5 2014 432
62. A. Cimino-Mathews, J.B. Foote, and L.A. Emens Immune targeting in breast cancer Oncology (Williston Park) 29 5 2015 375 385
63. G.J. Bates, S.B. Fox, C. Han, and et al. Quantification of regulatory T cells enables the identification of high-risk breast cancer patients and those at risk of late relapse J Clin Oncol. 24 34 2006 5373 5380
64. L. Benevides, C.R. Cardoso, D.G. Tiezzi, H.R. Marana, J.M. Andrade, and J.S. Silva Enrichment of regulatory T cells in invasive breast tumor correlates with the upregulation of IL-17A expression and invasiveness of the tumor Eur J Immunol. 43 6 2013 1518 1528
65. S.R. Bailey, M.H. Nelson, R.A. Himes, Z. Li, S. Mehrotra, and C.M. Paulos Th17 cells in cancer: the ultimate identity crisis Front Immunol 5 2014 276
66. Moasser MM, Krop IE. The evolving landscape of HER2 targeting in breast cancer. JAMA Oncol. 2015;1(8):1154-61.
67. G.D. Leonard, and S.M. Swain Ductal carcinoma in situ, complexities and challenges J Natl Cancer Inst. 96 12 2004 906 920
68. Z. Al-Mansour, T. Stockl, A. Khan, and et al. Significance of HER2/neu overexpression in pure ductal carcinoma in situ: a clinicopathologic study with long-term follow-up. 2013 Breast Cancer Symposium: ASCO University J Clin Oncol 31 Suppl 26 2013 Abstr 85
69. N. Liao, G.C. Zhang, Y.H. Liu, and et al. HER2-positive status is an independent predictor for coexisting invasion of ductal carcinoma in situ of the breast presenting extensive DCIS component Pathol Res Pract. 207 1 2011 1 7
70. E.A. Mittendorf, G.T. Clifton, J.P. Holmes, and et al. Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients Ann Oncol. 25 9 2014 1735 1742
71. E.A. Mittendorf, J.M. Gurney, C.E. Storrer, C.D. Shriver, S. Ponniah, and G.E. Peoples Vaccination with a HER2/neu peptide induces intra- and inter-antigenic epitope spreading in patients with early stage breast cancer Surgery 139 3 2006 407 418
72. L.A. Emens Breast cancer immunobiology driving immunotherapy: vaccines and immune checkpoint blockade Expert Rev Anticancer Ther. 12 12 2012 1597 1611
73. M.T. Hueman, A. Stojadinovic, C.E. Storrer, and et al. Levels of circulating regulatory CD4+CD25+ T cells are decreased in breast cancer patients after vaccination with a HER2/neu peptide (E75) and GM-CSF vaccine Breast Cancer Res Treat. 98 1 2006 17 29
74. M.T. Hueman, A. Stojadinovic, C.E. Storrer, and et al. Analysis of naive and memory CD4 and CD8 T cell populations in breast cancer patients receiving a HER2/neu peptide (E75) and GM-CSF vaccine Cancer Immunol Immunother. 56 2 2007 135 146
75. E.A. Mittendorf, G.T. Clifton, J.P. Holmes, and et al. Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02 Cancer 118 10 2012 2594 2602
76. G.K. Koski, U. Koldovsky, S. Xu, and et al. A novel dendritic cell-based immunization approach for the induction of durable Th1-polarized anti-HER-2/neu responses in women with early breast cancer J Immunother. 35 1 2012 54 65
77. B.J. Czerniecki, G.K. Koski, U. Koldovsky, and et al. Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion Cancer Res. 67 4 2007 1842 1852
78. A. Sharma, U. Koldovsky, S. Xu, and et al. HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact ductal carcinoma in situ Cancer 118 17 2012 4354 4362
79. M.N. Pollak, E.S. Schernhammer, and S.E. Hankinson Insulin-like growth factors and neoplasia Nat Rev Cancer. 4 7 2004 505 518
80. K.H. Park, E. Gad, V. Goodell, and et al. Insulin-like growth factor-binding protein-2 is a target for the immunomodulation of breast cancer Cancer Res. 68 20 2008 8400 8409
81. D.L. Cecil, K.H. Park, E. Gad, and et al. T-helper I immunity, specific for the breast cancer antigen insulin-like growth factor-I receptor (IGF-IR), is associated with increased adiposity Breast Cancer Res Treat. 139 3 2013 657 665
82. N.K. Nanda, and E.E. Sercarz The positively selected T cell repertoire: is it exclusively restricted to the selecting MHC? Int Immunol 7 3 1995 353 358
83. P.A. Cohen, L. Peng, G.E. Plautz, J.A. Kim, D.E. Weng, and S. Shu CD4+ T cells in adoptive immunotherapy and the indirect mechanism of tumor rejection Crit Rev Immunol. 20 1 2000 17 56
84. D.L. Cecil, G.E. Holt, K.H. Park, and et al. Elimination of IL-10-inducing T-helper epitopes from an IGFBP-2 vaccine ensures potent antitumor activity Cancer Res. 74 10 2014 2710 2718
85. M.L. Disis, W.C. Watt, and D.L. Cecil Th1 epitope selection for clinically effective cancer vaccines Oncoimmunology 3 9 2014 e954971
86. M.M. O'Meara, and M.L. Disis Therapeutic cancer vaccines and translating vaccinomics science to the global health clinic: emerging applications toward proof of concept Omics 15 9 2011 579 588
87. Disis ML, Gad E, Herendeen DR, et al. A multiantigen vaccine targeting neu, IGFBP-2, and IGF-IR prevents tumor progression in mice with preinvasive breast disease. Cancer Prev Res (Phila). 2013;6(12):1273-82.
88. S.D. Soysal, S. Muenst, J. Kan-Mitchell, and et al. Identification and translational validation of novel mammaglobin-A CD8 T cell epitopes Breast Cancer Res Treat. 147 3 2014 527 537
89. L. Li, S.P. Goedegebuure, T.P. Fleming, and W.E. Gillanders Developing a clinical development paradigm for translation of a mammaglobin-A DNA vaccine Immunotherapy 2015 1 3
90. R. Jaini, P. Kesaraju, J.M. Johnson, C.Z. Altuntas, D. Jane-Wit, and V.K. Tuohy An autoimmune-mediated strategy for prophylactic breast cancer vaccination Nat Med 16 7 2010 799 803
91. M.H. McLean, G.I. Murray, K.N. Stewart, and et al. The inflammatory microenvironment in colorectal neoplasia PLoS One 6 1 2011 e15366
92. F. Pages, A. Kirilovsky, B. Mlecnik, and et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer J Clin Oncol. 27 35 2009 5944 5951
93. B. Mlecnik, M. Tosolini, A. Kirilovsky, and et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction J Clin Oncol. 29 6 2011 610 618
94. E.K. Broussard, and M.L. Disis TNM staging in colorectal cancer: T is for T cell and M is for memory J Clin Oncol. 29 6 2011 601 603
95. S. Pernot, M. Terme, T. Voron, and et al. Colorectal cancer and immunity: what we know and perspectives World J Gastroenterol. 20 14 2014 3738 3750
96. M.A. Cheever, J.P. Allison, A.S. Ferris, and et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research Clin Cancer Res. 15 17 2009 5323 5337
97. E.T. Akporiaye, D. Bradley-Dunlop, S.J. Gendler, and et al. Characterization of the MUC1.Tg/MIN transgenic mouse as a model for studying antigen-specific immunotherapy of adenomas Vaccine 25 39-40 2007 6965 6974
98. M. Reuschenbach, M. von Knebel Doeberitz, and N. Wentzensen A systematic review of humoral immune responses against tumor antigens Cancer Immunol Immunother. 58 10 2009 1535 1544
99. P.L. Beatty, S. Narayanan, J. Gariepy, S. Ranganathan, and O.J. Finn Vaccine against MUC1 antigen expressed in inflammatory bowel disease and cancer lessens colonic inflammation and prevents progression to colitis-associated colon cancer Cancer Prev Res (Phila) 3 4 2010 438 446
100. T. Kimura, J.R. McKolanis, L.A. Dzubinski, and et al. MUC1 vaccine for individuals with advanced adenoma of the colon: a cancer immunoprevention feasibility study Cancer Prev Res (Phila) 6 1 2013 18 26
101. A.K. Tiwari, H.K. Roy, and H.T. Lynch Lynch syndrome in the 21st century: clinical perspectives Q J Med 2015 1 8
102. S.M. Woerner, E. Tosti, Y.P. Yuan, and et al. Detection of coding microsatellite frameshift mutations in DNA mismatch repair-deficient mouse intestinal tumors Mol Carcinog. 54 11 2015 1376 1386
103. Y. Schwitalle, M. Kloor, S. Eiermann, and et al. Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers Gastroenterology 134 4 2008 988 997
104. M. Reuschenbach, M. Kloor, M. Morak, and et al. Serum antibodies against frameshift peptides in microsatellite unstable colorectal cancer patients with Lynch syndrome Fam Cancer. 9 2 2010 173 179
105. E.R. Lutz, A.A. Wu, E. Bigelow, and et al. Immunotherapy converts nonimmunogenic pancreatic tumors into immunogenic foci of immune regulation Cancer Immunol Res 2 7 2014 616 631
106. S. Gettinger, and R.S. Herbst B7-H1/PD-1 blockade therapy in non-small cell lung cancer: current status and future direction Cancer J. 20 4 2014 281 289
107. J. Brahmer, K.L. Reckamp, P. Baas, and et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer N Engl J Med. 373 2 2015 123 135
108. M.A. Smit, E.M. Jaffee, and E.R. Lutz Cancer immunoprevention - the next frontier Cancer Prev Res (Phila) 7 11 2014 1072 1080
109. J. Wang, K.A. Reiss, R. Khatri, E. Jaffee, and D. Laheru Immune therapy in GI malignancies: a review J Clin Oncol. 33 16 2015 1745 1753
110. E. Lutz, C.J. Yeo, K.D. Lillemoe, and et al. A lethally irradiated allogeneic granulocyte-macrophage colony stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A phase II trial of safety, efficacy, and immune activation Ann Surg. 253 2 2011 328 335
111. D. Laheru, E. Lutz, J. Burke, and et al. Allogeneic granulocyte macrophage colony-stimulating factor-secreting tumor immunotherapy alone or in sequence with cyclophosphamide for metastatic pancreatic cancer: a pilot study of safety, feasibility, and immune activation Clin Cancer Res. 14 5 2008 1455 1463
112. C.B. Harley, A.B. Futcher, and C.W. Greider Telomeres shorten during ageing of human fibroblasts Nature 345 6274 1990 458 460
113. N.W. Kim, M.A. Piatyszek, K.R. Prowse, and et al. Specific association of human telomerase activity with immortal cells and cancer Science 266 5193 1994 2011 2015
114. D. Ponti, A. Costa, N. Zaffaroni, and et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties Cancer Res. 65 13 2005 5506 5511
115. G.L. Beatty, and R.H. Vonderheide Telomerase as a universal tumor antigen for cancer vaccines Expert Rev Vaccines. 7 7 2008 881 887
116. C.M. Counter, M. Meyerson, E.N. Eaton, and et al. Telomerase activity is restored in human cells by ectopic expression of hTERT (hEST2), the catalytic subunit of telomerase Oncogene 16 9 1998 1217 1222
117. W.C. Hahn, S.A. Stewart, M.W. Brooks, and et al. Inhibition of telomerase limits the growth of human cancer cells Nat Med 5 10 1999 1164 1170
118. B. Herbert, A.E. Pitts, S.I. Baker, and et al. Inhibition of human telomerase in immortal human cells leads to progressive telomere shortening and cell death Proc Natl Acad Sci U S A. 96 25 1999 14276 14281
119. B. Maecker, M.S. von Bergwelt-Baildon, K.S. Anderson, and et al. Rare naturally occurring immune responses to three epitopes from the widely expressed tumour antigens hTERT and CYP1B1 in multiple myeloma patients Clin Exp Immunol. 141 3 2005 558 562
120. J.A. Kyte Cancer vaccination with telomerase peptide GV1001 Expert Opin Investig Drugs. 18 5 2009 687 694
121. J.W. Shay, and W.E. Wright Telomerase: a target for cancer therapeutics Cancer Cell. 2 4 2002 257 265
122. P.F. Brunsvig, S. Aamdal, M.K. Gjertsen, and et al. Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer Cancer Immunol Immunother. 55 12 2006 1553 1564
123. J. Yan, P. Pankhong, T.H. Shin, and et al. Highly optimized DNA vaccine targeting human telomerase reverse transcriptase stimulates potent antitumor immunity Cancer Immunol Res 1 3 2013 179 189
124. E. Marzbani, C. Inatsuka, H. Lu, and M.L. Disis The invisible arm of immunity in common cancer chemoprevention agents Cancer Prev Res (Phila) 6 8 2013 764 773
125. H.E. Zeytin, A.C. Patel, C.J. Rogers, and et al. Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA.Tg/MIN mice Cancer Res. 64 10 2004 3668 3678
126. S. Zelenay, A.G. van der Veen, J.P. Bottcher, and et al. Cyclooxygenase-dependent tumor growth through evasion of immunity Cell 162 6 2015 1257 1270
127. Bosch FX, Robles C, Diaz M, et al. HPV-FASTER: broadening the scope for prevention of HPV-related cancer. Nat Rev Clin Oncol. Online publication 1 September 2015; doi:10.1038/nrclinonc.2015.146.